The GLP-1 Gold Rush: Lilly, Novo and New Rivals Chase a $260 Billion Market

GLP-1 receptor agonists are rapidly reshaping the pharmaceutical industry as the global obesity drug market accelerates toward a projected $260 billion opportunity over the next decade. Analysts estimate the broader GLP-1 therapeutics market reached $70.08 billion in 2025 and could expand to $201.79 billion by 2033, reflecting a compound annual growth rate of roughly 12.78%. The market’s explosive growth has been driven largely by two companies: Novo Nordisk and Eli Lilly, whose injectable GLP-1 receptor agonists have transformed obesity and diabetes treatment into one of the fastest-growing pharmaceutical segments globally. In 2025, Lilly’s tirzepatide franchise—marketed as Mounjaro for diabetes and Zepbound for obesity—generated approximately $36.5 billion in revenue, representing more than half of the company’s total sales.

Novo Nordisk continues to dominate the category’s early commercial phase. The company reported obesity-care sales of DKK 82.3 billion (≈ $12.0 billion USD)  in 2025, up 31% at constant exchange rates, driven primarily by semaglutide products Wegovy and Ozempic. Yet the industry’s competitive landscape is rapidly evolving as oral GLP-1 drugs, multi-receptor agonists, and next-generation metabolic therapies move toward regulatory milestones.

From Lifestyle Treatment to Cardiometabolic Medicine

The strategic narrative around GLP-1 therapies has shifted significantly over the past two years. Initially framed as weight-loss medications, these drugs are increasingly positioned as cardiometabolic disease treatments addressing obesity-related comorbidities including diabetes, cardiovascular disease, and sleep apnea. 

A major turning point came in December 2024 when the FDA approved Eli Lilly’s Zepbound for moderate-to-severe obstructive sleep apnea, following positive results from the SURMOUNT-OSA trial. The study showed patients experienced up to a 63% reduction in apnea events compared with placebo.

Regulatory expansion into additional indications is reshaping payer dynamics. Historically, Medicare excluded anti-obesity medications under the Medicare Modernization Act, limiting patient access. However, in late 2025 the Centers for Medicare & Medicaid Services (CMS) introduced the BALANCE Model, a demonstration program that will begin covering GLP-1 therapies for eligible Medicare beneficiaries starting in July 2026, with broader Part D implementation expected by 2027. The program includes a $50 monthly out-of-pocket cap for participating patients, signaling a major shift in how governments treat obesity therapeutics—from lifestyle drugs to essential cardiometabolic interventions.

Novo Nordisk: Defending the First-Mover Advantage

Novo Nordisk built the modern GLP-1 market through decades of expertise in peptide manufacturing and diabetes therapies. The company’s next major asset is CagriSema, a fixed-dose combination of semaglutide and the amylin analogue cagrilintide. Clinical trials have demonstrated significant weight-loss potential. The REDEFINE-1 (NCT05567796) and REDEFINE-2 (NCT05379595) trials reported weight reduction approaching 20–23%, positioning the therapy as one of the most potent obesity drugs currently in development. Novo Nordisk is widely expected to pursue regulatory submissions in the United States and Europe following completion of the Phase 3 program.

However, the company faces increasing pressure from competing mechanisms. Novo Nordisk’s share price briefly declined in early 2026 after REDEFINE-4 results failed to demonstrate non-inferiority against tirzepatide, highlighting the intensifying competition between the industry’s two dominant players. Novo is also expanding its oral GLP-1 strategy, advancing higher-dose oral semaglutide formulations (25 mg and 50 mg) for obesity. Oral therapies could dramatically expand the addressable market by reducing the reliance on injections, a barrier for many patients.

Eli Lilly: Betting on Multi-Receptor Agonists

Eli Lilly’s strategy focuses on maximizing metabolic efficacy through multi-receptor biology. Tirzepatide already combines GLP-1 and GIP receptor agonism, and the company is advancing retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors. 

In Phase 2 trials, retatrutide demonstrated up to 24% weight loss at 48 weeks, among the highest reductions observed in obesity pharmacotherapy. The ongoing TRIUMPH Phase 3 program is expected to produce pivotal data beginning in 2026.

Lilly is simultaneously pursuing oral GLP-1 innovation through orforglipron, a non-peptide small-molecule therapy designed to eliminate injection requirements. The company has prepared for a potential launch by building $1.5 billion in pre-launch inventory, reflecting confidence in large-scale demand. If approved, orforglipron could significantly expand patient access to obesity treatments, particularly in markets where injectable biologics remain difficult to distribute.

The Second Wave: Amgen, Roche, and AstraZeneca

While Novo Nordisk and Lilly dominate the current market, several major pharmaceutical companies are advancing competitive therapies aimed at differentiating on dosing frequency, efficacy, or metabolic outcomes.

• Amgen: Developing MariTide (AMG 133), a long-acting GLP-1/GIP antagonist peptide designed for once-monthly dosing. Phase 2 results demonstrated weight loss approaching 20% at 52 weeks, and the ongoing MARITIME Phase 3 program will determine whether extended dosing intervals can improve patient adherence.
• Roche: Following its acquisition of Carmot Therapeutics, Roche is advancing CT-388, a dual GLP-1/GIP receptor agonist. Early clinical data showed placebo-adjusted weight reduction of approximately 22.5% at 48 weeks, and the company is preparing Phase 3 trials later this year.
• AstraZeneca: Entered the oral GLP-1 race through elecoglipron, which recently achieved primary endpoints in the VISTA and SOLSTICE trials. The company further strengthened its metabolic pipeline in 2026 by paying $1.2 billion upfront to CSPC Pharmaceuticals for rights to additional obesity therapies.

Biotech Challengers and Potential Acquisition Targets

Beyond large pharmaceutical companies, several biotech firms are emerging as potential disruptors—and acquisition targets. 

• Viking Therapeutics is developing VK2735, a dual GLP-1/GIP receptor agonist currently in Phase 2 trials. Early data showed weight reductions exceeding 14% at 13 weeks.
• Structure Therapeutics is advancing GSBR-1290, an oral small-molecule GLP-1 receptor agonist designed to compete directly with Lilly’s orforglipron.
• Zealand Pharma is pursuing combination metabolic therapies including amylin analogues, which could complement GLP-1 mechanisms to enhance weight-loss outcomes.

With many large pharmaceutical companies facing major patent expirations later this decade, analysts expect GLP-1 innovators to become prime targets for strategic acquisitions.

Global Expansion: Obesity as a Worldwide Market

Although the United States currently represents the largest commercial opportunity for GLP-1 drugs, global demand is rising rapidly.

According to the World Health Organization, more than 1 billion people worldwide now live with obesity, a figure that has nearly tripled since 1975. Cardiometabolic diseases—including diabetes and cardiovascular conditions—remain the leading causes of mortality globally.

Emerging markets, particularly China and the Middle East, are experiencing rapid increases in obesity prevalence due to urbanization and dietary changes. Pharmaceutical companies are therefore positioning GLP-1 therapies as global cardiometabolic platforms rather than niche obesity treatments.

Macro Outlook: The Next Phase of the GLP-1 Economy

The GLP-1 market is entering a new phase defined less by first-mover advantage and more by clinical differentiation, manufacturing capacity, and pricing strategy. From the outside looking in the industry appears to be entering a “post-shortage” era where market leaders are defined by their ability to provide data-backed secondary health outcomes.

1. Pricing Pressure is Intensifying: Oral small-molecule therapies such as orforglipron could introduce lower-cost alternatives to injectable biologics, potentially establishing a new pricing floor in the obesity market. Lilly’s strategy suggests orforglipron pricing may start as low as $149 per month on the LillyDirect platform. This provides a tangible “retained value” benchmark for orals compared to the ~$1,000 list price of injectables, forcing injectables to justify their premium through superior clinical data.
2. Commoditization vs. Premium Value (The “Multi-Outcome” Shift): As basic weight loss becomes a commodity—evidenced by the 77% of large employers prioritizing GLP-1 cost management in 2026—manufacturers are pivoting to “Premium” indications to avoid generic pressure. For example, Novo Nordisk is moving into Alzheimer’s disease and kidney disease. The inference here is that a drug that “just loses weight” will face step-therapy requirements behind cheaper generics like liraglutide, whereas a drug with MACE (cardiovascular) or MASH (liver) protection will maintain preferred formulary status.
3. The “Muscle Preservation” Standard: The next competitive metric is “quality of weight loss.” Roche’s current testing of CT-388 in combination with myostatin inhibitors and AstraZeneca’s stated goal to develop products that ensure “more fat loss, less muscle loss” support the claim that clinical superiority in 2027 will be defined by body composition, not just total mass reduction.
4. Manufacturing CAPEX as a Moat: Barriers to entry have shifted from biology to industrial scale. Eli Lilly invested approximately $7.8 billion in manufacturing expansion during 2025, while Novo Nordisk announced DKK 45 billion in capital expenditures for 2026, aimed at scaling peptide production. Crucially the cost of scaling fill-finish capacity effectively locks out smaller competitors who lack the balance sheet to build multi-national manufacturing hubs.
5. Increased M&A Activity: Analysts anticipate increased merger and acquisition activity across the metabolic drug sector as large pharmaceutical companies seek to secure positions in what is rapidly becoming one of the industry’s most lucrative therapeutic categories.

With the obesity epidemic continuing to expand worldwide, GLP-1 therapies are poised to reshape the treatment of cardiometabolic disease—and redefine the competitive landscape of the global pharmaceutical industry.

Author

Bernice Lottering